Patents Assigned to Cobra Biologics Limited
  • Patent number: 8026098
    Abstract: The invention relates to a process for the removal of selectable marker gene sequences, in particular antibiotic gene sequences, from nucleic acid molecules. The invention further relates to the application of this process in the unlabelled integration and deletion of chromosomal genes and in controlling gene expression.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: September 27, 2011
    Assignee: Cobra Biologics Limited
    Inventors: Rocky Marc Cranenburgh, Alexandra Elizabeth Bloor
  • Patent number: 7611883
    Abstract: The invention relates to a system for stable maintenance of a plasmid, to host cells for use in this system and to methods of using the system to obtain a plasmid useful in medical applications. In particular, the invention provides transformed host cell containing: i) a chromosomal gene which inhibits cell growth; and ii) a plasmid encoding an antisense sequence, wherein the antisense sequence encoded by the plasmid inhibits the action of the chromosomal gene, thereby permitting cell growth and a method for stable maintenance of a plasmid in a host cell in vivo.
    Type: Grant
    Filed: November 22, 2004
    Date of Patent: November 3, 2009
    Assignee: Cobra Biologics Limited
    Inventor: Rocky Marc Cranenburgh
  • Publication number: 20070259430
    Abstract: The invention relates to a process for the removal of selectable marker gene sequences, in particular antibiotic gene sequences, from nucleic acid molecules. The invention further relates to the application of this process in the unlabelled integration and deletion of chromosomal genes and in controlling gene expression.
    Type: Application
    Filed: July 1, 2005
    Publication date: November 8, 2007
    Applicant: Cobra Biologics Limited
    Inventors: Rocky Cranenburgh, Alexander Bloor
  • Publication number: 20070110721
    Abstract: The invention relates to a system for stable maintenance of a plasmid, to host cells for use in this system and to methods of using the system to obtain a plasmid useful in medical applications. In particular, the invention provides transformed host cell containing: i) a chromosomal gene which inhibits cell growth; and ii) a plasmid encoding an antisense sequence, wherein the antisense sequence encoded by the plasmid inhibits the action of the chromosomal gene, thereby permitting cell growth and a method for stable maintenance of a plasmid in a host cell in vivo.
    Type: Application
    Filed: November 22, 2004
    Publication date: May 17, 2007
    Applicant: Cobra Biologics Limited
    Inventor: Rocky Cranenburgh
  • Patent number: 6780632
    Abstract: The invention relates to host cells and methods of preparing a substantially RNA-free cellular component, comprising culturing cells producing the cellular component in a medium and lysing the cells to produce a cell lysate, wherein the cell lysate contains the cellular component and sufficient RNase activity to degrade substantially all of the RNA molecules present in the cell lysate. The invention also relates to substantially RNA-free cellular components.
    Type: Grant
    Filed: April 14, 1999
    Date of Patent: August 24, 2004
    Assignee: Cobra Biologics Limited
    Inventors: Julian Alexis John Hanak, Steven Geraint Williams
  • Patent number: 6743780
    Abstract: A system is described which utilizes a novel system of repressor titration for maintenance of a plasmid useful in gene therapy and production of a recombinant protein. The system utilizes a transformed host cell containing a plasmid including an operator susceptible to binding by a repressor expressed in trans, a first chromosomal gene encoding the repressor, and a second chromosomal gene that is functionally associated with an operator and essential for cell growth, wherein the plasmid is present in the cell in sufficient numbers to titrate the repressor such that the essential gene is expressed, thereby permitting cell growth.
    Type: Grant
    Filed: November 12, 1999
    Date of Patent: June 1, 2004
    Assignee: Cobra Biologics Limited
    Inventors: Julian A. J. Hanak, Steven G. Williams, Scott D. Gorman, David J. Sherratt